Posted by Michael Wonder on 15 Nov 2024
Highlights from the 11-14 November 2024 CHMP meeting
15 November 2024 - The EMA’s CHMP has recommended eight medicines for approval at its November 2024 meeting.
The committee recommended granting a conditional marketing authorisation for Augtyro (repotrectinib), a medicine intended for the treatment of adults and adolescents with advanced solid tumours, and adults with locally advanced or metastatic non-small cell lung cancer.
